We report a 39-year-old female patient who underwent HLA-identical sibling allogeneic BMT for CML in accelerated phase. Severe pancytopenia refractory to G-CSF associated with progressive splenomegaly and RBC/ platelet transfusion dependency were present from day +60 after BMT. MRD assessed by FISH and RT-PCR multiplex for BCR-ABL rearrangement was negative, and complete chimerism was documented by VNTR on days +100, +180, +360 and 2 years after BMT. Splenectomy was performed on day +225 and pancytopenia resolved but chronic extensive graft-versus-host disease developed, with hepatic cholestasis, diffuse scleroderma and sicca-like syndrome. She was sequentially and progressively treated with different immunosuppressive therapy combinations with no clear benefit. On day +940, she presented with infection over the previously present ulcers on both limbs, which culminated in septic shock and death on day +1041. We conclude that, although splenectomy may reverse poor graft function after allogeneic BMT, hyposplenism may trigger or worsen chronic extensive GVHD leading to increased morbidity and mortality. Bone Marrow Transplantation (2003) 32, 333-335. doi:10.1038/sj.bmt.1704122 Keywords: BMT; chronic GVHD; splenectomy Allogeneic BMT is a therapeutic option for many hematologic malignancies and the only curative available treatment for CML to date. Graft-versus-host disease (GVHD) remains one of the major complications and has a high mortality rate. Splenectomy has been undertaken to reverse poor graft function because of hypersplenism after allogeneic BMT, with satisfactory results.
Allogeneic BMT is a therapeutic option for many hematologic malignancies and the only curative available treatment for CML to date. Graft-versus-host disease (GVHD) remains one of the major complications and has a high mortality rate. Splenectomy has been undertaken to reverse poor graft function because of hypersplenism after allogeneic BMT, with satisfactory results. [1] [2] [3] Previous studies indicate that surgical or functional postallogeneic BMT hyposplenism may be associated with a higher incidence of chronic extensive GVHD. 4 However there are conflicting data in the literature about the relationship between splenectomy and worsening of GVHD. [5] [6] [7] [8] We report a case in which this association clearly occurred.
Case report
39-year-old female patient presented with fatigue and abdominal fullness. Massive splenomegaly was found and WBC showed marked leukocytosis (160 Â 10 9 /l) with leftshifted myeloid series and basophilia. Bone marrow aspiration and Ph1 chromosome positivity confirmed the diagnosis of CML. She was admitted for HLA identical sibling donor BMT, and the conditioning regimen consisted of busulphan (16 mg/kg)/cyclophosphamide (120 mg/kg). 9 GVHD prophylaxis consisted of short-term methotrexate plus cyclosporine (CyS). 10 Engraftment occurred on day +28. On day +60, a routine CBC showed pancytopenia (WBC 2.2 Â 10 9 /l with ANC 0.602 Â 10 9 /l, hemoglobin of 7.2 g/dl and platelet count of 23 Â 10 9 /l) associated with progressive splenomegaly. Bone marrow aspiration and biopsy revealed a normocellular marrow. Over the next 5 months, she had eight febrile neutropenic episodes requiring hospital admission and treatment with broadspectrum antibiotics. Daily subcutaneous 5 mg/kg G-CSF infusions were given for 14 days with no improvement. She received a total of 19 U of RBC and 75 random units of platelets. G-Band karyotyping was normal. MRD searched by FISH and RT-PCR multiplex for BCR-ABL rearrangements were negative and complete chimerism was documented by VNTR on days +100, +180, +360 and 2 years after BMT. We concluded that the patient was entirely donor on chimerism studies and had evidence of hypersplenism.
As she remained pancytopenic and transfusion dependent for more than 7 months after BMT, splenectomy was performed on day +225. The spleen had no morphological or cytogenetic evidence of tumor. Pancytopenia and dependency on transfusion resolved after splenectomy.
Edema and rash in both forearms and hands were seen on day +260 and evolved into a diffuse scleroderma ( Figure 1 ). As part of the extensive c-GVHD, a sicca-like syndrome and liver cholestasis were diagnosed at that time. She was sequentially treated with CyS plus prednisone and weekly high-dose immunoglobulin infusions. CyS was discontinued on day +921 because of acute renal failure. On day +486, she developed Herpes Zoster lesions on the trunk that progressed to local ulceration with secondary infection and concomitant ulceration of both limbs ( Figure 2 ). She underwent hyperbaric oxygen therapy with some recovery. The generalized scleroderma evolved to affect the trunk and limbs. A year post transplant, PUVA therapy associated with daily MMF (2 g), thalidomide (600 mg) and prednisone (80 mg) were sequentially and progressively initiated. Several admissions for infectious complications were required. On day +1034, she had a Staphylococcus aureus systemic infection with worsening of the limb ulceration, culminating in septic shock and death on day +1041.
Discussion
We describe a patient who underwent allogeneic BMT for CML in accelerated phase and developed a severe and persistent pancytopenia in the post transplant period associated with splenomegaly and hypersplenism. Splenectomy was performed and the pancytopenia resolved, but a progressive de novo chronic extensive GVHD emerged after the surgery. All immunosuppressive measures adopted failed to change the course of the chronic GVHD which had a fatal outcome.
Post transplant hypersplenism was first described in 1992 and should be considered in patients presenting with pancytopenia and splenomegaly after allogeneic BMT. It has been associated with splenic hypervascularity, and expanded vascular capacity and proliferation of infused stem cells in the spleen, possibly related to physical impediment of flow. 3 Splenectomy has been shown to resolve pancytopenia in 11 previously reported cases, with no associated comorbidity. [1] [2] [3] Accordingly, in the present case, splenectomy successfully resolved the pancytopenia.
There is controversy in the literature regarding the relationship between splenectomy and chronic GVHD. Ringde´n et al 5 have shown an increased incidence of acute GVHD and higher death rate in patients splenectomized before BMT. The same European group confirmed later that splenectomy was an important risk factor for acute and chronic GVHD on bivariate analysis and in only chronic GVHD on multivariate analysis. 6 Michallet et al 7 evaluated 157 patients who underwent BMT from an HLAidentical sibling and found that splenectomy was the most important factor determining GVHD severity on multivariate analysis. However, a more recent retrospective analysis to evaluate the role of splenectomy on BMT outcome showed no significant influence of splenectomy on acute or chronic GVHD, although it was associated with an increased risk for all grades of acute GVHD, but this was not statistically significant. 8 The exact mechanism of the influence of splenectomy on GVHD incidence and severity is not known. The most likely hypothesis is that the spleen functions as a 'filter' for activated T cells by the activity of HLA-DR and CD1a-positive cells (dendritic cells).
11 Donor-derived alloreactive T cells, post-thymic activated CD4 + T cells and T cells immunoreactive to minor HLA antigens, which are extremely important in the pathogenesis of chronic GVHD, could then possibly be 'cleared' by the spleen. By this mechanism, the spleen may also play a role in modulating the activation of different helper T-cell subsets (Th1 vs Th2) minimizing the effects of cytokines secreted by Th2 cells (IL-4, IL-5, IL-10), which predominate in chronic GVHD. 12 The other two hypotheses include the role of the spleen in the modulation of infections, 13 and its production of an immunosuppressive peptide in animal studies, never found in human studies.
14 Infection was Chronic extensive GVHD after splenectomy in BMT for CML CA Rodrigues et al constantly present in this case: before splenectomy because of severe neutropenia and after splenectomy because of severe chronic GVHD, despite a normal neutrophil count. We believe that infection was also an important risk factor in the development of chronic GVHD in this case. It is also important to emphasize that the patient remained in continuous complete remission during the whole post transplant period and that a chronic GVHDassociated GVL effect may have had an important role.
We conclude that, although splenectomy may reverse poor graft function after allogeneic BMT, surgical hyposplenia may trigger or worsen chronic extensive GVHD leading to an increase in morbidity and mortality.
